黴漿菌檢測市場規模、佔有率及成長分析（按產品、技術、應用、最終用戶和地區）－2025 年至 2032 年產業預測

2023 年全球黴漿菌檢測市場規模為 8.324 億美元，預計將從 2024 年的 8.9733 億美元成長到 2032 年的 16.3644 億美元，預測期內（2025-2032 年）的複合年成長率為 7.8%。

由於製藥和生物技術領域的污染問題日益嚴重，黴漿菌檢測市場預計將大幅成長。生物製藥行業不斷成長的研究舉措和對黴漿菌檢測套組日益成長的需求是主要的成長動力。由於醫療保健基礎設施的改善以及歐洲藥品管理局（EMA）和美國食品藥物管理局（FDA）等機構加強監管，要求對生技藥品和疫苗進行嚴格測試，預計新興市場將促進這一趨勢。此外，Minerva Biolabs GmbH 的高靈敏度 VenorGeM Advance 偵測等技術創新正在提高偵測的準確性和效率。由於這種綜合需求、監管支援和技術創新，黴漿菌檢測市場預計將在未來幾年大幅擴張。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術分析

黴漿菌檢測市場規模（按產品）

• 市場概覽
• 裝置
• 套件和試劑
  • PCR檢測
  • 核酸檢測試劑套件
  • 污垢
  • 拆卸套件
  • 標準與管理
  • 其他
• 服務

黴漿菌檢測市場規模（按技術）

• 市場概覽
• PCR
• ELISA
• 直接分析
• 間接分析
• 微生物培養技術
• 酵素法

黴漿菌檢測市場規模（依應用）

• 市場概覽
• 細胞株測試
• 病毒檢測
• 電池報廢檢查
• 其他

黴漿菌檢測市場規模（依最終用戶分類）

• 市場概覽
• 學術研究所
• 細胞庫
• 合約研究組織
• 製藥和生物技術公司
• 其他

黴漿菌檢測市場規模

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Thermo Fisher Scientific Inc.（USA）
• Merck KGaA（Germany）
• Lonza Group Ltd.（Switzerland）
• Charles River Laboratories International Inc.（USA）
• Eurofins Scientific SE（Luxembourg）
• Roche Diagnostics（Switzerland）
• Agilent Technologies Inc.（USA）
• Bio-Rad Laboratories Inc.（USA）
• Sartorius AG（Germany）
• bioMerieux SA（France）
• Asahi Kasei Corporation（Japan）
• American Type Culture Collection（ATCC）（USA）
• Bionique Testing Laboratories Inc.（USA）
• InvivoGen（USA）
• PromoCell GmbH（Germany）
• Biological Industries Israel Beit Haemek Ltd.（Israel）
• Creative Bioarray（USA）
• Mycoplasma Experience（UK）
• Norgen Biotek Corp.（Canada）
• Biotools B & M Labs SA（Spain）

結論和建議

Global Mycoplasma Testing Market size was valued at USD 832.4 million in 2023 and is poised to grow from USD 897.33 million in 2024 to USD 1636.44 million by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The mycoplasma testing market is poised for significant growth, driven by increased contamination issues within the pharmaceutical and biotechnology sectors. Rising research initiatives and heightened demand for mycoplasma testing kits in biopharmaceutical industries are primary growth catalysts. Emerging markets are expected to contribute to this trend, bolstered by improved healthcare infrastructures and regulatory mandates from bodies like the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA), which enforce stringent testing for biologics and vaccines. Moreover, technological innovations, exemplified by Minerva Biolabs GmbH's highly sensitive VenorGeM Advance assay, are enhancing testing accuracy and efficiency. This synergistic growth of demand, regulatory support, and innovation positions the mycoplasma testing market for substantial expansion in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Mycoplasma Testing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Mycoplasma Testing Market Segments Analysis

Global Mycoplasma Testing Market is segmented by Product, Technology, Application, End-User and region. Based on Product, the market is segmented into Instruments, Kits & Reagents and Services. Based on Technology, the market is segmented into PCR, ELISA, Direct Assay, Indirect Assay, Microbial Culture Techniques and Enzymatic Methods. Based on Application, the market is segmented into Cell Line Testing, Virus Testing, End of Production Cells Testing and Others. Based on End-User, the market is segmented into Academic Research Institutes, Cell Banks, Contract Research Organizations, Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Mycoplasma Testing Market

The Global Mycoplasma Testing market is experiencing a significant surge in demand, primarily fueled by the growing research and development efforts in the biotechnology and pharmaceutical sectors, particularly concerning cell-based therapies and vaccines. As the reliance on cell lines for production intensifies, the necessity for contamination-free cell line streams has become critical. Moreover, as companies place a greater emphasis on quality assurance in their research processes, the demand for mycoplasma testing continues to escalate, alongside the need for more stringent and effective testing protocols. This trend highlights the crucial role of mycoplasma testing in ensuring product safety and efficacy in the industry.

Restraints in the Global Mycoplasma Testing Market

The Global Mycoplasma Testing market faces significant challenges due to a shortage of skilled personnel proficient in contemporary testing methodologies. Effective mycoplasma testing relies heavily on expert knowledge and proper implementation of testing procedures, and the scarcity of adequately trained professionals could impede progress in this field. This issue is particularly pronounced in developing countries, where resources for training and education are often limited, further obstructing the widespread adoption of mycoplasma testing solutions. The lack of expertise not only affects the implementation of existing techniques but also hinders innovations and improvements that could benefit the industry as a whole.

Market Trends of the Global Mycoplasma Testing Market

The Global Mycoplasma Testing market is experiencing a significant trend towards automation within laboratory operations, particularly in the biopharmaceutical sector. Automated systems streamline mycoplasma testing processes, drastically reducing testing times and enhancing productivity while minimizing human error. As biopharmaceutical companies increasingly emphasize process efficiency and consistency in quality, the demand for advanced mycoplasma testing technologies is projected to rise. This shift towards automation aligns with broader industry trends aimed at optimizing research and manufacturing practices, ultimately driving growth and innovation in the mycoplasma testing market as companies seek to ensure product safety and efficacy.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Mycoplasma Testing Market Size by Product & CAGR (2025-2032)

• Market Overview
• Instruments
• Kits & Reagents
  • PCR Assays
  • Nucleic Acid Detection Kits
  • Stains
  • Elimination Kits
  • Standards & Controls
  • Others
• Services

Global Mycoplasma Testing Market Size by Technology & CAGR (2025-2032)

• Market Overview
• PCR
• ELISA
• Direct Assay
• Indirect Assay
• Microbial Culture Techniques
• Enzymatic Methods

Global Mycoplasma Testing Market Size by Application & CAGR (2025-2032)

• Market Overview
• Cell Line Testing
• Virus Testing
• End of Production Cells Testing
• Others

Global Mycoplasma Testing Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Academic Research Institutes
• Cell Banks
• Contract Research Organizations
• Pharmaceutical & Biotechnology Companies
• Others

Global Mycoplasma Testing Market Size & CAGR (2025-2032)

• North America (Product, Technology, Application, End-User)
  • US
  • Canada
• Europe (Product, Technology, Application, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Technology, Application, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Technology, Application, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Technology, Application, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck KGaA (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lonza Group Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories International Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific SE (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sartorius AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• bioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Asahi Kasei Corporation (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• American Type Culture Collection (ATCC) (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bionique Testing Laboratories Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• InvivoGen (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PromoCell GmbH (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biological Industries Israel Beit Haemek Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Creative Bioarray (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mycoplasma Experience (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Norgen Biotek Corp. (Canada)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Biotools B & M Labs S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations